Baseline characteristics
| Variable . | Subcategory . | KRd-ASCT (n = 36) . | Elo-KRd (n = 23) . | Dara-KRd (n = 38) . | Total (N = 97) . | P value . |
|---|---|---|---|---|---|---|
| Age, median (range), y | 58 (40-80) | 62 (43-77) | 55 (40-72) | 59 (40-80) | .78 | |
| Sex, n (%) | Female | 20 (56) | 6 (26) | 13 (34) | 39 (40) | .049 |
| Male | 16 (44) | 17 (74) | 25 (66) | 58 (60) | ||
| Race, n (%) | Black | 5 (14) | 1 (4) | 11 (29) | 17 (18) | |
| White | 29 (81) | 16 (70) | 21 (55) | 66 (68) | .046 | |
| Other/not reported | 2 (6) | 6 (26) | 6 (16) | 14 (14) | ||
| Ethnicity, n (%) | Hispanic | 4 (11) | 2 (8) | 4 (11) | 10 (10) | |
| Non-Hispanic | 32 (89) | 16 (70) | 34 (89) | 82 (85) | 1 | |
| Other/not reported | 0 | 5 (22) | 0 | 5 (5) | ||
| ISS, n (%) | I | 17 (47) | 8 (35) | 21 (55) | 46 (47) | |
| II | 15 (42) | 10 (43) | 11 (29) | 36 (37) | .62 | |
| III | 4 (11) | 3 (13) | 6 (16) | 13 (13) | ||
| Unknown | 0 | 2 (8) | 0 | 2 (2) | ||
| ECOG, n (%) | 0 | 17 (47) | 11 (48) | 30 (79) | 58 (60) | .01 |
| 1 | 17 (47) | 12 (52) | 8 (21) | 37 (38) | ||
| 2 | 2 (6) | 0 | 0 | 2 (2) | ||
| Cytogenetic risk, n (%) | Standard | 26 (72) | 12 (52) | 18 (47) | 54 (56) | .08 |
| High | 10 (28) | 11 (48) | 20 (53) | 43 (44) | ||
| del(17p) | 3 (8) | 5 (22) | 6 (16) | 14 (14) | .38 | |
| t(4;14) | 2 (6) | 1 (4) | 8 (21) | 11 (11) | .08 | |
| t(14;16) | 2 (6) | 0 | 3 (8) | 5 (5) | .44 | |
| gain/amp(1q) | 3 (8) | 8 (35) | 12 (32) | 23 (24) | .02 |
| Variable . | Subcategory . | KRd-ASCT (n = 36) . | Elo-KRd (n = 23) . | Dara-KRd (n = 38) . | Total (N = 97) . | P value . |
|---|---|---|---|---|---|---|
| Age, median (range), y | 58 (40-80) | 62 (43-77) | 55 (40-72) | 59 (40-80) | .78 | |
| Sex, n (%) | Female | 20 (56) | 6 (26) | 13 (34) | 39 (40) | .049 |
| Male | 16 (44) | 17 (74) | 25 (66) | 58 (60) | ||
| Race, n (%) | Black | 5 (14) | 1 (4) | 11 (29) | 17 (18) | |
| White | 29 (81) | 16 (70) | 21 (55) | 66 (68) | .046 | |
| Other/not reported | 2 (6) | 6 (26) | 6 (16) | 14 (14) | ||
| Ethnicity, n (%) | Hispanic | 4 (11) | 2 (8) | 4 (11) | 10 (10) | |
| Non-Hispanic | 32 (89) | 16 (70) | 34 (89) | 82 (85) | 1 | |
| Other/not reported | 0 | 5 (22) | 0 | 5 (5) | ||
| ISS, n (%) | I | 17 (47) | 8 (35) | 21 (55) | 46 (47) | |
| II | 15 (42) | 10 (43) | 11 (29) | 36 (37) | .62 | |
| III | 4 (11) | 3 (13) | 6 (16) | 13 (13) | ||
| Unknown | 0 | 2 (8) | 0 | 2 (2) | ||
| ECOG, n (%) | 0 | 17 (47) | 11 (48) | 30 (79) | 58 (60) | .01 |
| 1 | 17 (47) | 12 (52) | 8 (21) | 37 (38) | ||
| 2 | 2 (6) | 0 | 0 | 2 (2) | ||
| Cytogenetic risk, n (%) | Standard | 26 (72) | 12 (52) | 18 (47) | 54 (56) | .08 |
| High | 10 (28) | 11 (48) | 20 (53) | 43 (44) | ||
| del(17p) | 3 (8) | 5 (22) | 6 (16) | 14 (14) | .38 | |
| t(4;14) | 2 (6) | 1 (4) | 8 (21) | 11 (11) | .08 | |
| t(14;16) | 2 (6) | 0 | 3 (8) | 5 (5) | .44 | |
| gain/amp(1q) | 3 (8) | 8 (35) | 12 (32) | 23 (24) | .02 |
P values refer to differences between the 3 trial populations.
ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System.